Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT -2.56% Cash-to-Debt is 0.33 as of Jun. 2026, which is 90% below its 10-year median of 3.43. The stock has 7 warning signs investors should review. Among 984 Drug Manufacturers companies, Vitura Health ranks worse than 68.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vitura Health's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.33.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vitura Healthcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vitura Health's Cash-to-Debt or its related term are showing as below:
ASX:VIT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: 3.43 Max: 14.74
Current: 0.33
During the past 8 years, Vitura Health's highest Cash to Debt Ratio was 14.74. The lowest was 0.33. And the median was 3.43.
ASX:VIT's Cash-to-Debt is ranked worse than 68.5% of 984
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs ASX:VIT: 0.33
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vitura Health Cash-to-Debt Related Terms
Vitura Health Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vitura Health's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vitura Health's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a Cash-to-Debt of 0.33 as of Jun. 2026. This is 90% below median its historical median of 3.43. Over the past decade, Vitura Health's Cash-to-Debt has ranged from 0.33 to 14.74. According to the industry distribution chart, Vitura Health ranks #674 out of 984 companies in the Drug Manufacturers industry, placing it in the top 68.5%.
Is Vitura Health's Cash-to-Debt too high?
Vitura Health's current Cash-to-Debt of 0.33 is 90% below median its 10-year median of 3.43. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 14.74. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Vitura Health's value of 0.33 is 65.6% below this industry median. Based on the distribution chart, Vitura Health ranks #674 out of 984 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #674 out of 984 companies for Cash-to-Debt. This places Vitura Health in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Vitura Health's value of 0.33 is 65.6% below this benchmark. Historically, Vitura Health's own Cash-to-Debt has ranged from 0.33 to 14.74 over the past decade. While the company's 10-year median is 3.43 vs. the industry median of 0.96, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current Cash-to-Debt of 0.33 is 65.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Cash-to-Debt is 0.33, which is 90% below median its own 10-year median of 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.07, compared to a current price of A$0.02 — trading 72.9% below its estimated fair value. The current Cash-to-Debt is 0.33, which is 90% below median its 10-year median of 3.43 and 65.6% below the Drug Manufacturers industry median of 0.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Cash-to-Debt is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
